Descripción de la empresa
Avanos Medical, Inc. operates as a medical technology provider delivering specialized device solutions across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company focuses primarily on digestive health products, including Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal devices. This enterprise functions within the Healthcare sector, specifically classified under the Medical Devices industry, where it competes in a market requiring high technical precision and regulatory compliance. The company demonstrates a mid-cap valuation with a market capitalization of $636.69M and generates annual revenue of $701.20M based on trailing twelve-month data. These financial figures indicate that Avanos Medical holds a significant operational footprint, supported by a workforce of 2,287 employees, positioning it as a substantial player in the global medical device landscape rather than a niche micro-cap entity.
Salud financiera
The company reports a revenue figure of $701.20M for the trailing twelve months, while its net income stands at -$72,900,000, revealing a substantial gap between top-line generation and bottom-line profitability. This negative net income indicates a challenging cost structure where operating expenses and other deductions exceed gross profits, resulting in a loss despite solid sales volume. The company achieves an EBITDA of $54.40M, which suggests that core operational cash generation remains positive even after accounting for the net loss recognized in standard accounting measures. Free cash flow is reported at $46.01M, providing the organization with financial flexibility to fund operations, manage working capital, or pursue strategic initiatives without immediate reliance on external financing. Gross margin stands at 50.5%, reflecting the high-cost nature of manufacturing medical devices where production efficiency is critical. Operating margin is compressed to 2.0%, indicating that administrative and selling expenses are consuming nearly all of the gross profit before interest and taxes. Profit margin is negative at -10.4%, confirming that the company is currently burning cash on a net basis, which impacts overall shareholder value accumulation. The balance sheet shows a cash position of $89.80M against total debt of $129.10M, resulting in a debt-to-equity ratio of 16.59. This high leverage ratio suggests a leveraged balance sheet where the company carries significant debt obligations relative to its equity base. The current ratio is 2.15, indicating that the company holds sufficient current assets to cover its short-term liabilities with a comfortable cushion. Return on Equity is -9.1%, which reveals that management is currently destroying shareholder value rather than generating returns on the capital invested by equity holders. Return on Assets stands at 0.9%, showing that the company generates minimal positive returns on its total asset base, consistent with its net loss position.
Evaluación de valoración
The trailing P/E ratio is listed as N/A due to the negative net income, while the forward P/E is projected at 10.95. The divergence between a non-existent trailing multiple and a forward multiple of 10.95 implies that the market expects earnings to turn positive or significantly improve in the coming year to justify the current share price. The price-to-book ratio is 0.82, indicating that the stock trades at a discount to its book value, suggesting the market values the company below the replacement cost of its tangible assets. The price-to-sales ratio is 0.91, providing a revenue-based valuation metric that shows the market prices the company at slightly less than one dollar of revenue per dollar of sales. The EV/EBITDA multiple stands at 12.43, which offers an enterprise value perspective that accounts for debt and cash, suggesting the company is valued at roughly 12 times its earnings before interest, taxes, depreciation, and amortization. The 52-week trading range spans from a low of $9.30 to a high of $15.68, and the current share price sits within this band, reflecting market uncertainty regarding the turnaround of earnings. The beta value is 1.05, indicating that the stock exhibits slightly higher volatility than the broader market, moving 5% more aggressively than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is recorded at 0.7%, while earnings growth is N/A due to the negative net income reported in the trailing twelve months. The lack of earnings growth, quantified as N/A, implies that profitability has not yet recovered to support positive earnings growth rates that would outpace or match the modest revenue expansion. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning no cash is distributed to shareholders from earnings. This absence of dividend distribution indicates that the company retains all earnings to reinvest into growth initiatives, R&D, or debt reduction rather than paying out dividends to shareholders. The overall growth and income profile is characterized by stable but slow revenue expansion and a complete absence of current income generation or dividend payments.